# Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Healthy Toddlers

> **NCT00387569** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 99 (estimated)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** MnB vaccine rLP8026
- **BIOLOGICAL:** MnB vaccine rLP8026
- **BIOLOGICAL:** MnB vaccine rLP8026

## Key facts

- **NCT ID:** NCT00387569
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 99 (ESTIMATED)
- **Last updated:** 2008-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00387569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00387569, "Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Healthy Toddlers". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00387569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*